SCHEMBL6955377

SCHEMBL6955377

CCc1cc(C#N)c(Cl)nc1C

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
ALDH1A1 P00352 3/20 0.46
KHK P50053 1/20 0.42
PKM P14618 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PGK1 P00558 1/20 0.38
KDM4E B2RXH2 5/20 0.38
GAA P10253 3/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.37
KDM5A P29375 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9846221 0.86 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1
SCHEMBL33526375 0.79 NPSR1 (0.59) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1
SCHEMBL30442040 0.77 NPSR1 (0.57) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1
SCHEMBL2394013 0.77 NPSR1 (0.57) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1
SCHEMBL20303775 0.77 NPSR1 (0.57) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1
SCHEMBL9262255 0.76 GAA (0.57) CYP1A2CYP2C9CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL23369596 0.75 POLB (0.43) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1
SCHEMBL16828824 0.74 NPSR1 (0.54) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1
SCHEMBL16370648 0.74 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1
SCHEMBL6050497 0.74 KHK (0.62) CYP1A2CYP2C9CYP2C19NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed
US-5387512-A Incubating the compound 3-(2-benzoxazol-2-yl-ethyl)-5-ethyl-6-methyl-2-(1H)-pyridinone with liver tissue, oxidation to form a hydroxy group attenching ethyl branch MERCK & CO. INC. (US) 1995-02-07 US disclosed
US-5308854-A 2-benzoxazolylalkyl substituted pyridin-2(1H)(thi)ones; AIDS MERCK & CO., INC. (US) 1994-05-03 US disclosed
US-5202243-A Biosynthetic hydroxylation yields polymerase inhibitors MERCK & CO., INC. (US) 1993-04-13 US disclosed
US-5185251-A Treatment of HIV and AIDS MERCK & CO., INC. (US) 1993-02-09 US disclosed
EP-0484071-A2 Synergism of HIV reverse transcriptase inhibitors MERCK & CO. INC. (US) 1992-05-06 EP disclosed
EP-0462808-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP disclosed
EP-0462800-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 EP disclosed